Transasia looks forward to sustain momentum in 2022 through key initiatives

The last two years have proved to be a turning point for Indian healthcare and the industry is looking to build on the experience. In the current financial year, the government too has shown its strong commitment to strengthen the industry and turn the spotlight on public healthcare. The allocation of ₹64,180 crore towards healthcare and implementation of various schemes, is giving an impetus to improvement in healthcare infrastructure.

Particularly for the diagnostic industry, the pandemic has led to a shift in mindset towards disease prevention and the important role of diagnosis as the first step towards achieving health and wellness. Prevention costs just 2% of what it costs to cure, and hence for our country it makes sense to invest in disease prevention. With a dedicated focus on early testing, the opportunities seem bright for the diagnostic industry. In fact, by end of 2022, the diagnostic market alone is anticipated to grow to USD 32 bn in India. NITI Aayog in its recent report pointed that diagnostic and pathology centers will expand in the times to come and the sector has a promising future.

Various initiatives will continue to drive the growth of the medtech industry through 2022 and Transasia will continue to contribute to this growth:

Making in lndia – Transasia Bio-Medicals has been a pioneer in offering Made in India diagnostic equipment right from its inception. We already have five state-of-the-art manufacturing hubs in India and in 2022 we intend to further scale-up our production capacity and expand our manufacturing base.

Meeting the present and future needs through innovative and technologically advanced products – While Covid-19 has taken centre-stage, there are other diseases that need immediate attention. Speaking particularly of infectious diseases, transfusion transmitted infections continue to be a major concern not just in India but globally as well. India has taken significant steps in line with the WHO guidelines to limit the prevalence of TTIs, and early screening is an important aspect in achieving the elimination goals.

On its part, Transasia continues to play a crucial role in offering quality solutions. Transasia’s comprehensive portfolio for Covid-19 offers solutions for diagnosis, testing and sero-surveillance. In fact, the newly launched rapid test kit detects all Covid-19 variants including Omicron, Delta+ and Deltacron.

Transasia has also recently introduced ErbaLisa HCV Gen 4 Ag+Ab, India’s first and only indigenously developed 4th generation ELISA assay for early detection of Hepatitis C Virus and the ErbaQik rapid test kit for four critical infections namely HIV, HBsAg, HCV and Syphilis.

Going forward, our teams in R&D and manufacturing continue to work on new and advanced diagnostic systems in CLIA, Molecular, high-end hematology, Artificial Intelligence, LIS, etc. Also in the offing is a ‘Total Lab Automation’ solution for mid and large size laboratories. All these will make Erba-Transasia among the top five companies globally to have ‘Total Solutions in Laboratory Diagnostics’.

2022 will see us launching some of these hi-tech solutions that will enhance clinical outcomes. Besides this we continue to upgrade our products based on customer expectations.

Technological advancements – An increasing demand for lab tests has made it essential to develop technologies which assist in faster diagnosis. Manufacturers are developing systems integrated with AI and Machine Learning that is making diagnostic equipment easy-to-use, thereby increasing their reach and ensuring quality of diagnosis.

On this front, Transasia has integrated remote monitoring with its range of biochemistry analyzers, for preventive maintenance thus reducing downtime. Its high-end urine chemistry and sediment analyzer, Laura XL, is integrated with AI and digital microscopy for accurate reporting. These analyzers are already playing a crucial role in meeting the diagnostic needs of chain labs and large government institutes.

Making these technologies affordable and accessible to benefit tier 3 and 4 towns and villages, continues to remain a challenge for manufacturers. To address this, Transasia is already working on developing point-of-care diagnostic tests for other body fluids, like saliva, making it convenient for end-users.

Global expansion – We are already exporting ‘Made in India’ sophisticated diagnostic equipment to over 100 countries. In 2022, we look to expand this number to cover 130 countries.